{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T22:41:28.025535+00:00","company":{"ticker":"DSGN","cik":1807120,"company_name":"Design Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"37168189c14500d81bcc42c7bc265d31bd2519e0","cik":1807120,"ticker":"DSGN","company_name":"Design Therapeutics, Inc.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $17.6 million for the quarter ended March 31, 2026.","period_text":"the three months ended March 31, 2026","report_date":"2026-04-28","result_type":"reported_results","revenue_text":null},"claim":"Design Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income Net loss was $17.6 million for the quarter ended March 31, 2026..","evidence_excerpt":"Net loss was $17.6 million for the quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-187012","anchor_url":"https://secwatch.observer/filing/0001193125-26-187012#claim-37168189c14500d81bcc42c7bc265d31bd2519e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm"},{"fact_type":"earnings_release","fact_key":"9f3b0d7e27f810f0f9bb253cbb15ef20afec6928","cik":1807120,"ticker":"DSGN","company_name":"Design Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$11.1 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":null},"claim":"Design Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $11.1 million.","evidence_excerpt":"Net loss was $11.1 million for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-055645","anchor_url":"https://secwatch.observer/filing/0000950170-24-055645#claim-9f3b0d7e27f810f0f9bb253cbb15ef20afec6928","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm"}]}